Onco Wiki / Bandeira vermelha

CML patient with positive HBV serology (HBsAg+ or anti-HBc+) — TKI therapy is associated...

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDRF-CML-INFECTION-SCREENING
TipoSinal de alerta
Estadoreviewed 2026-04-25 | pending_clinical_signoff
DoençasDIS-CML
FontesSRC-ELN-CML-2020 SRC-NCCN-MPN-2025

Origem da bandeira vermelha

DefiniçãoCML patient with positive HBV serology (HBsAg+ or anti-HBc+) — TKI therapy is associated with HBV reactivation in case reports; mandatory HBV testing pre-TKI + active prophylaxis (entecavir / tenofovir) if HBsAg+, monitoring if anti-HBc+ only
Direcção clínicainvestigar
Categoriarastreamento de infecções

Lógica de Desencadeamento

{
  "any_of": [
    {
      "finding": "hbsag",
      "value": "positive"
    },
    {
      "finding": "anti_hbc_total",
      "value": "positive"
    },
    {
      "finding": "hcv_rna",
      "value": "positive"
    },
    {
      "finding": "hiv_status",
      "value": "positive"
    }
  ],
  "type": "composite"
}

Notas

Direction "investigate" — surfaces a workup-prerequisite annotation. CML TKI-related HBV reactivation is rare but reported (especially with immunosuppression-dose TKI shifts and post-TFR discontinuation). HBV testing recommended before initiating any TKI per ELN 2020 + NCCN. STUB — requires clinical co-lead signoff.

Usado por

Algoritmos

Indicação